Vertex Pharmaceuticals (VRTX) EBT Growth (3y) (2012 - 2026)
Powered by 
Analysis
Vertex Pharmaceuticals (VRTX) EBT Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 19.70% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -103.74% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 6.22% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 12.16% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 103.79% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 24.03% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 38.36% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -42.82% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | 64.03% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.22% |
| Mar 31, 2026 | 12.01% |
| Dec 31, 2025 | 7.32% |
| Sep 30, 2025 | 3.35% |
| Jun 30, 2025 | 7.79% |
| Mar 31, 2025 | -8.54% |
| Dec 31, 2024 | 9.28% |
| Sep 30, 2024 | 4.17% |
| Jun 30, 2024 | -324.92% |
| Mar 31, 2024 | 15.93% |
| Dec 31, 2023 | 8.90% |
| Sep 30, 2023 | 16.50% |
| Jun 30, 2023 | 12.09% |
| Mar 31, 2023 | 10.68% |
| Dec 31, 2022 | 16.73% |
| Sep 30, 2022 | 155.34% |
| Jun 30, 2022 | 46.30% |
| Mar 31, 2022 | 43.94% |
| Dec 31, 2021 | 199.26% |
| Sep 30, 2021 | 99.43% |